Phase III clinical trial - Sein métastatique RH+
EMBER-3 (J2J-OX-JZLC)
Sein métastatique RH+
Ouvert depuis le: 12.06.2023
Site: Paris
Ouvert depuis le: 03.03.2022
Site: Saint-Cloud
Public cible
Adulte
EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy
Description de l'essai
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have breast cancer that is advanced or has spread to another part of the body. Study participation could last up to 5 years.
Liens utiles
